Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Egetis Therapeutics AB's enterprise value is $338.31 Mil.
Egetis Therapeutics AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-37.97 Mil. Therefore, Egetis Therapeutics AB's EV-to-EBITDA for today is -8.91.
The historical rank and industry rank for Egetis Therapeutics AB's EV-to-EBITDA or its related term are showing as below:
PDPHF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.83 Med: -5.28 Max: 0.49
Current: -9.05
During the past 13 years, the highest EV-to-EBITDA of Egetis Therapeutics AB was 0.49. The lowest was -16.83. And the median was -5.28.
PDPHF's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 13.12
vs PDPHF: -9.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Egetis Therapeutics AB (OTCPK:PDPHF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Egetis Therapeutics AB's PE Ratio (TTM) for today is calculated as:
Egetis Therapeutics AB's share price for today is $0.6353.
Egetis Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.095.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDPHF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Egetis Therapeutics AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's EV-to-EBITDA falls into.
Egetis Therapeutics AB's current Enterprise Value is $338.31 Mil.
Egetis Therapeutics AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB (PDPHF) has a EV-to-EBITDA of -8.91 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Egetis Therapeutics AB. According to the industry distribution chart, Egetis Therapeutics AB ranks #999999 out of 401 companies in the Biotechnology industry.
Is Egetis Therapeutics AB's EV-to-EBITDA too high?
Egetis Therapeutics AB's current EV-to-EBITDA is -8.91. Based on the distribution chart, Egetis Therapeutics AB ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Egetis Therapeutics AB has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #999999 out of 401 companies for EV-to-EBITDA. This places Egetis Therapeutics AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.12, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Egetis Therapeutics AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current EV-to-EBITDA is -8.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Egetis Therapeutics AB (PDPHF) has a current EV-to-EBITDA of -8.91. The stock's GF Value™ is $0.51, compared to a current price of $0.64 — trading 24.6% above its estimated fair value. The current EV-to-EBITDA is -8.91. Egetis Therapeutics AB's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current EV-to-EBITDA is -8.91 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued.
The current stock price of $0.64 is trading 24.6% above its estimated GF Value™ of $0.51.
Key valuation signals for PDPHF:
EV-to-EBITDA: -8.91
GF Value™: $0.51 vs. price of $0.64 (24.6% above fair value)
No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
54GF Score
Get the complete analysis for PDPHF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDPHF has been successfully added to your 
